Study of BHV-1400 in IgA Nephropathy

NCT07054684 · tracked via the Priya Life Science UK tracker

Sponsor

Biohaven Therapeutics Ltd.

Phase

Phase 1

Started

2025-07-30

Last updated

2026-06-23

Condition(s) studied

IgA Nephropathy

Investigational drug(s) / intervention(s)

BHV-1400

BHV-1400: BHV-1400 is delivered subcutaneously (SC)

Study summary

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).

Eligibility

Sex

ALL

Min age

18 Years

Max age

65 Years

Healthy volunteers

Key Inclusion Criteria: 1\. Participants must have biopsy-confirmed IgA Nephropathy Key Exclusion Criteria: 1. Any secondary IgAN 2. Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause

Primary outcome measure(s)

Number of participants with Serious AEs (SAEs), AEs leading to discontinuation, deaths — Up to 1 year
To assess the safety and tolerability of BHV-1400. This objective will be measured by assessing the number of unique subjects with SAEs, moderate or severe AEs, AEs leading to discontinuation or deaths
Number of participants with Grade 3-4 treatment-emergent laboratory abnormalities — Up to 1 year
To assess the safety and tolerability of BHV-1400. This objective will be measured by assessing the number of unique subjects with Grade 3 or 4 treatment-emergent laboratory abnormalities.

Trial sites (15)

Facility	City	Region	Status
Site-001	Farmington	Connecticut	Recruiting
Site-003	Miami Lakes	Florida	Recruiting
Site-011	Miami Lakes	Florida	Recruiting
Site-013	Orlando	Florida	Recruiting
Site-005	Pembroke Pines	Florida	Recruiting
Site-008	Lawrenceville	Georgia	Recruiting
Site-009	Hinsdale	Illinois	Recruiting
Site-012	Indianapolis	Indiana	Recruiting
Site-015	Shelby	Michigan	Recruiting
Site-006	Chesterfield	Missouri	Recruiting
Site-002	Dakota Dunes	South Dakota	Recruiting
Site-014	Houston	Texas	Recruiting
Site-004	Houston	Texas	Recruiting
Site-016	Salt Lake City	Utah	Recruiting
Site-007	Leicester	United Kingdom	Recruiting

More Biohaven Therapeutics Ltd. trials in the UK

Long-term Safety and Tolerability of BHV-7000 Enrolling by invitation

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Active, not recruiting

Other trials for the same condition

A Study of Zigakibart in Adults With IgA Nephropathy Active, not recruiting

Atrasentan in Patients With Proteinuric Glomerular Diseases Active, not recruiting

Atrasentan in Patients With IgA Nephropathy Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07054684 on ClinicalTrials.gov ↗ ← All trials in the UK